Clinical Trials Logo

Clinical Trial Summary

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).


Clinical Trial Description

This study will be conducted in two stages. Stage 1 is a 48-week, dose-escalation, open-label evaluation of AR-14034 SR. Two cohorts will be enrolled, for an approximate total of 10 subjects. Subjects in both cohorts will attend visits through Week 48 for assessment of safety and preliminary treatment effects. Stage 2 is a 56-week (plus extension) double-masked, active comparator, randomized, parallel group evaluation of AR-14034 SR compared with aflibercept. Approximately 130 subjects will be enrolled and randomized 2:2:1 to AR-14034 SR lower dose, AR-14034 SR higher dose, or aflibercept dosed as labelled. Subjects will attend visits through Week 56 for assessment of safety and treatment effects. A 16-week open label extension phase will be conducted thereafter. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05769153
Study type Interventional
Source Aerie Pharmaceuticals
Contact Alcon Call Center
Phone 1-888-451-3937
Email alcon.medinfo@alcon.com
Status Recruiting
Phase Phase 1/Phase 2
Start date December 6, 2023
Completion date March 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04543331 - Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
Recruiting NCT05904691 - Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration Phase 1
Completed NCT05282004 - Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit Phase 3
Active, not recruiting NCT04764656 - Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal
Completed NCT05269966 - Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) Phase 4
Completed NCT05161806 - Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe Phase 3
Recruiting NCT04657289 - A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) Phase 3
Recruiting NCT06116890 - Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration Phase 2
Recruiting NCT06075147 - The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
Terminated NCT04746963 - Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration Phase 1/Phase 2
Enrolling by invitation NCT05210803 - Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
Recruiting NCT04514653 - RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) Phase 2
Not yet recruiting NCT06398080 - An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
Active, not recruiting NCT05989126 - Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) Phase 3